Addiction Clinical Trial
Official title:
Prevalence of New Psychoactive Substances Use Among Outpatient of Addiction Management Clinic in Assiut University Hospital
According to the United Nations Office on Drugs and Crime [UNODC] World Drug Report, the annual prevalence of drug use seemed to be stable for the past few years. However, new psychoactive substances (NPS) have increased drastically in both supply and demand.Many NPS were discovered at the same time as other drugs, and it was simply, for whatever reasons, these other drugs became popular. The majority of these substances are chemicals produced by tweaking or altering the molecular structure of previous well-known psychoactive agents such as cannabis, cocaine, methylenedioxymeth-amphetamine (or MDMA, commonly known as ecstasy), and lysergic acid diethylamide (or LSD), which are being sold as "legal highs," "research chemicals," "herbal highs," "party pills," or "plant food" in an attempt to stay ahead of the law prohibiting the sale and use of psychoactive drugs.Substance abuse rates in Egypt have hit 10%, or double the global average. Tramadol is the most abused substance, followed by cannabis and heroin.In the past two years, two new drugs - known as Strox and Voodoo - have hit the Egyptian market.Voodoo is a combination of an aromatic plant, like marjoram or incense, which is infused with a synthetic cannabinoid that is up to 100 times as powerful as natural marijuana. Shabu is another name for methamphetamine hydrochloride, also known as crystal meth. Meth is a highly addictive stimulant that causes its user irreversible harm, physically and mentally. Pregabalin is increasingly being reported as possessing a potential for misuse.
In 2014, the estimated population who were suffering from drug abuse and drug-related
disorders reached over 29 million worldwide, making it a global health challenge. Moreover,
43.5 per million people die annually from associated drug use. According to the United
Nations Office on Drugs and Crime [UNODC] World Drug Report, the annual prevalence of drug
use seemed to be stable for the past few years. However, new psychoactive substances (NPS)
have increased drastically in both supply and demand.
The term "new psychoactive substances" had been legally defined earlier by the European Union
as a new narcotic or psychotropic drug, in pure form or in a preparation, that is not
scheduled under the Single Convention on Narcotic Drugs of 1961 or the Convention on
Psychotropic Substances of 1971, but which may pose a public health threat comparable to that
posed by substances listed in those conventions. Although the NPS terminology seems to imply
the creation of novel drugs, many are not new. In fact, most psychoactive drugs (that later
became abused) have been in use for at least a century. Many NPS were discovered at the same
time as other drugs, and it was simply, for whatever reasons, these other drugs became
popular. The majority of these substances are chemicals produced by tweaking or altering the
molecular structure of previous well-known psychoactive agents such as cannabis, cocaine,
methylenedioxymeth-amphetamine (or MDMA, commonly known as ecstasy), and lysergic acid
diethylamide (or LSD), which are being sold as "legal highs," "research chemicals," "herbal
highs," "party pills," or "plant food" in an attempt to stay ahead of the law prohibiting the
sale and use of psychoactive drugs.
On the basis of that definition, European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) identified the following groups of substances covered by its early warning system on
NPS:
- Phenethylamines, which encompass a wide range of substances that may exhibit stimulant,
entactogenic or hallucinogenic effects.
- Tryptamines, which include a number of substances that have predominantly hallucinogenic
effects.
- Piperazines, which are represented, inter alia, by mchlorophenylpiperazine (mCPP) and
BZP, both of which are central nervous system stimulants.
- Synthetic cathinones, which have stimulant effects. The main cathinone derivatives are
the semi-synthetic methcathinone and the synthetic compounds mephedrone, methylone and
MDPV.
- Synthetic cannabinoids are functionally similar to THC, the active compound of cannabis.
- Other substances reported to the early warning system include various plant-derived and
synthetic psychoactive substances (e.g. indanes, benzodifuranyls, narcotic analgesics,
synthetic cocaine derivatives, ketamine and phencyclidine derivatives), which do not
strictly belong to any of the above-mentioned drug families. Also included are a number
of medicinal products and derivatives.
NPS are formulated in a variety of forms, and when sold in the market, many contain mixtures
of different substances some including controlled drugs. Smoked, ingested, snorted, or
injected NPS can produce a variety of psychotropic effects, which can be similar to those
related to the controlled substances they contain or to the chemical entities that they are
derived from. Based on their clinical effects, NPS can be classified as stimulants,
empathogens-entactogens, sedative-hypnotic-anxiolytics, dissociatives, and hallucinogens.
Alternatively, they can be classified according to their chemical class as phenethylamines,
piperazines, tryptamines, synthetic cathinones, alkylindoles (synthetic cannabinoids), and
arylcyclohexylamines.
Substance abuse rates in Egypt have hit 10%, or double the global average. Tramadol is the
most abused substance, followed by cannabis and heroin. The ancient culture of Egypt includes
an equally ancient history of drug and alcohol abuse. Opium and hashish have been used in
Egypt for centuries, and recent tests have found cocaine in mummified remains—a discovery
that has confounded historians who considered that the coca plant was purely a South American
phenomenon until recent times.It was in the 1980s that use of narcotics began to escalate to
serious levels. Currently, Egypt is one of Africa's top cultivators of cannabis and opium
poppies. The number of hectares discovered that are dedicated to growing addictive substances
has been increasing steadily over the last decade. The amount of "bango"—the local name for
marijuana—seizures have also been increasing from 60,000 kg per year up to 80,000 kg and
above.
In the past two years, two new drugs - known as Strox and Voodoo - have hit the Egyptian
market.Voodoo is a combination of an aromatic plant, like marjoram or incense, which is
infused with a synthetic cannabinoid that is up to 100 times as powerful as natural
marijuana. The most common brand is "Mister Nice Guy", which is sold in a small bag decorated
with a smiley emoticon. The bag has a warning that reads "relaxing incense, not edible".
Strox is also made with an aromatic plant like marjoram and incense, which is then sprayed
with active medical substances used as pain relievers in case of cramps or stomach aches,
like atropine, hyoscine and hyoscyamine. These substances can have psychotropic effects when
taken in large doses. Usually, these two drugs are mixed with tobacco and then smoked.
Shabu is another name for methamphetamine hydrochloride, also known as crystal meth. Meth is
a highly addictive stimulant that causes its user irreversible harm, physically and
mentally.it is a white, odorless substance. Typically, you will find it in a crystal
formation or crystalline powder. It tends to be bitter in taste. Sometimes, it's combined
with caffeine or other chemicals. Furthermore, it can be packaged in the form of a pill for
easy measurement and distribution.
Pregabalin is widely used in neurology, psychiatry and primary healthcare. Pregabalin has
been identified within the 30 most prescribed medications in the USA in 2011. In Europe,
pregabalin is approved for the treatment of epilepsy (partial seizures), neuropathic pain and
generalised anxiety disorder. In the USA, although not approved for anxiety, pregabalin is
further approved for fibromyalgia and post-herpetic neuralgia. The molecule is however also
often prescribed off-label for a range of clinical conditions, including: bipolar disorder;
alcohol/narcotic withdrawal states; attention-deficit/hyperactivity disorder; restless legs'
syndrome; trigeminal neuralgia and non-neuropathic pain disorders .Pregabalin is increasingly
being reported as possessing a potential for misuse [10]. In the UK, for example, pregabalin
prescribing has increased, respectively, by 350 and 150 % in just 5 years. In Norway,
Persheim et al. analysed changes for the period 2008-2011 in the drug reimbursement system
relating to expenditures for potentially addictive drugs in patients with
severe/non-malignant chronic pain, and found that about one-third of the approved
applications were for pregabalin. In parallel with this, there is an anecdotally growing
black market, with pregabalin being allegedly available without prescriptions through online
pharmacies.
Medications obtained by patients for treatment of common ailments, without a prescription
from a physician, are known as over-the-counter (OTC) or non-prescription medications. OTC
medications provide prevention and treatment for a wide range of conditions, including but
not limited to headaches, common cold, musculoskeletal pain, allergies, tobacco dependence,
and heartburn. Multiple OTC medications have abuse potential. Commonly abused medications
include antihistamines, sleep aids, caffeine, ephedrine, pseudoephedrine, antitussives and
expectorants, dextromethorphan, laxatives, anabolic steroids, and sildenafil. Laxatives are
abused for weight loss and high antihistamines doses are used for euphoria.
Tropicamide is an antimuscarinic ophthalmic solution used to produce short-acting mydriasis
and cycloplegia. Topical abuse of ophthalmic solutions has been reported, but intravenous
(IV) abuse of tropicamide seems to be a new phenomenon.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03576768 -
QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt
|
N/A | |
Completed |
NCT04110626 -
Realistic Evaluation of Expériences Animées, a School-based Intervention in Nouvelle Aquitaine
|
||
Completed |
NCT03007940 -
Using NIATx Strategies to Implement Integrated Services in Routine Care
|
N/A | |
Not yet recruiting |
NCT04030858 -
The INFINITE Study: A Prospective Investigation of a Nutrient-dense Diet in Early Addiction Recovery
|
N/A | |
Completed |
NCT03347643 -
The Effectiveness of tDCS on Internet Game Addiction
|
Phase 2 | |
Active, not recruiting |
NCT02836080 -
Integrated Collaborative Care Teams for Youth With Mental Health and/or Addiction Challenges (YouthCan IMPACT)
|
N/A | |
Completed |
NCT03221985 -
ESM Pilot: Mobile Phones and Psychology
|
N/A | |
Completed |
NCT02556060 -
Lamotrigine for Ketamine Dependence Trial
|
Phase 2/Phase 3 | |
Completed |
NCT02812810 -
Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) Low-frequency on Craving in Smoking Dependence
|
N/A | |
Completed |
NCT01531153 -
Cognitive Enhancement as a Target for Cocaine Pharmacotherapy
|
N/A | |
Recruiting |
NCT05976646 -
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
|
Phase 1/Phase 2 | |
Completed |
NCT04409106 -
The Turkish Version of the Parental Smartphone Use Management Scale (PSUMS)
|
||
Not yet recruiting |
NCT06459609 -
Effect of Protein Supplementation on Craving in Subjects Hospitalised for Addiction Treatment
|
N/A | |
Recruiting |
NCT05595759 -
Violence Against Women in Patients With Alcohol Substance Addiction Training
|
N/A | |
Completed |
NCT04099173 -
A Brief Mindfulness-Based Intervention for Suicidal Ideation
|
N/A | |
Recruiting |
NCT04959643 -
Systematic Screening for Viral Hepatitis B and C at the PASS Consultation of the Montpellier University Hospital
|
||
Completed |
NCT04133688 -
Mobile App in Addiction
|
N/A | |
Recruiting |
NCT04063267 -
Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder
|
Phase 2 | |
Completed |
NCT05114577 -
Recovery Sleepers: A Pilot Study of a Sleep Health Intervention for College Students in Recovery
|
N/A | |
Terminated |
NCT02671240 -
Prognosis of Behavioral Addiction in Parkinson's Disease
|